Dashboard
Novo Nordisk A/S
NVONYSEFor informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Universal block
Live market data + trailing fundamentals.
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 19Trial readoutClinicalTrials.gov
Phase 2 trial NCT06409130 of NNC0194-0499, cagrilintide and semaglutide in alcohol-related liver disease completed.
- Nov 19Trial readoutClinicalTrials.gov
Phase 3 trial NCT06065540 of CagriSema vs semaglutide/cagrilintide/placebo in T2D completed.
- Nov 18Trial initiationClinicalTrials.gov
Novo Nordisk posts Phase 1 trial NCT07944118 (NOT_YET_RECRUITING) examining Zenagamtide fasting and dosing effects on gastric emptying in overweight/obese T2D/非
- Nov 18OtherClinicalTrials.gov
Update on NCT07739901 Korean real-world MASLD/MASH outcomes study; sponsor Novo Nordisk; status ACTIVE_NOT_RECRUITING as of 2026-11-18.
- Nov 17Trial initiationClinicalTrials.gov
Novo Nordisk Phase 1 trial NCT07940582 (NNC0721-5186) in overweight/obese women listed as not yet recruiting.
- Nov 17Trial initiationClinicalTrials.gov
Phase 1/2 trial NCT07940803 initiated for NNC0662-3168 in weight management and Type 2 diabetes (not yet recruiting).
- Nov 17Trial initiationClinicalTrials.gov
Phase 1 trial NCT07845578 recruiting: high-dose s.c. semaglutide effect on gastric emptying in excess body weight subjects.
- Nov 16Trial readoutClinicalTrials.gov
Phase 3 trial NCT06588504 for dasiglucagon vs glucagon in hypoglycemia completed (Japan, T1D adults/adolescents)
- Nov 16OtherClinicalTrials.gov
Phase 3 trial NCT07220759 (cagrilintide, overweight/obesity + T2D) status updated to ACTIVE_NOT_RECRUITING.
- Nov 16OtherSEC
Form 6-K foreign issuer report filed.
- Nov 16Trial readoutClinicalTrials.gov
Phase 3 trial NCT04775082 (SCALE KIDS) for weight management in children with obesity updated to ACTIVE_NOT_RECRUITING status.
- Nov 12Trial initiationClinicalTrials.gov
Novo Nordisk Phase 3 trial NCT07931573 (AMBITION 3) for Zenagamtide vs semaglutide in T2D, status NOT_YET_RECRUITING.
- Nov 12Trial initiationClinicalTrials.gov
Novo Nordisk Phase 3 trial NCT07931495 of Zenagamtide in Type 2 diabetes, status NOT_YET_RECRUITING.
- Nov 12Trial initiationClinicalTrials.gov
Phase 3 trial NCT07931599 initiated (NOT_YET_RECRUITING) comparing Zenagamtide vs semaglutide in T2D patients on metformin/SGLT2i.
- Nov 12Trial initiationClinicalTrials.gov
Novo Nordisk Phase 3 trial NCT07931547 of Zenagamtide in Type 2 diabetes with CKD, not yet recruiting.
- Nov 10OtherClinicalTrials.gov
Phase 3 trial NCT07400107 (NNC0487-0111 vs semaglutide, weight loss/T2D) status updated to ACTIVE_NOT_RECRUITING.
- Nov 10Trial initiationClinicalTrials.gov
Phase 1 trial NCT07587710 recruiting for NNC0487-0111 PK in hepatic impairment vs normal liver function
- Nov 10Trial initiationClinicalTrials.gov
Phase 1 trial NCT07896109 for NNC9836-0001 safety in healthy and Type 2 diabetes participants now recruiting.
- Nov 9OtherSEC
Novo Nordisk A/S filed Form 6-K with the SEC on 2026-11-09.
- Nov 6OtherClinicalTrials.gov
Phase 3 trial NCT07533175 (NNC0487-0111, obesity + T2D) status updated to ACTIVE_NOT_RECRUITING
Not financial advice — research and opinion only. Disclosures